Nanomedicine revolutionizes epilepsy treatment: overcoming therapeutic hurdles with nanoscale solutions

References

• Thijs RD, Surges R, O’Brien TJ, et al. Epilepsy in adults. Lancet. 2019;393(10172):689–701. doi: 10.1016/S0140-6736(18)32596-0
   PubMed Web of Science ®Google Scholar
• Manole AM, Sirbu CA, Mititelu MR, et al. State of the art and challenges in epilepsy–a narrative review. J Pers Med. 2023;13(4):623. doi: 10.3390/jpm13040623
   PubMed Web of Science ®Google Scholar
• Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology. 2017;88:296–303. doi: 10.1212/WNL.0000000000003509
   PubMed Web of Science ®Google Scholar
• Perucca P, Scheffer IE, Kiley M. The management of epilepsy in children and adults. Med J Aust. 2018;208(5):226–233. doi: 10.5694/mja17.00951
   PubMed Web of Science ®Google Scholar
• Falco-Walter JJ, Scheffer IE, Fisher RS. The new definition and classification of seizures and epilepsy. Epilepsy Res. 2018;139:73–79. doi: 10.1016/j.eplepsyres.2017.11.015
   PubMed Web of Science ®Google Scholar
• Kim YS, Choi J, Yoon BE. Neuron-glia interactions in neurodevelopmental disorders. Cells. 2020;9(10):2176. doi: 10.3390/cells9102176
   PubMed Web of Science ®Google Scholar
• Kobylarek D, Iwanowski P, Lewandowska Z, et al. Advances in the potential biomarkers of epilepsy. Front Neurol. 2019;10:685. doi: 10.3389/fneur.2019.00685
   PubMed Web of Science ®Google Scholar
• Enright N, Simonato M, Henshall DC. Discovery and validation of blood microRnas as molecular biomarkers of epilepsy: ways to close current knowledge gaps. Epilepsia Open. 2018;3(4):427–436. doi: 10.1002/epi4.12275
   PubMedGoogle Scholar
• Banote RK, Akel S, Zelano J. Blood biomarkers in epilepsy. Acta Neurol Scand. 2022;146(4):362–368. doi: 10.1111/ane.13616
   PubMed Web of Science ®Google Scholar
• Vezzani A, Balosso S, Ravizza T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat Rev Neurol. 2019;15(8):459–472. doi: 10.1038/s41582-019-0217-x
   PubMed Web of Science ®Google Scholar
• Gu X, Hao D, Xiao P. Research progress of Chinese herbal medicine compounds and their bioactivities: fruitful 2020. Chin Herb Med. 2022;14(2):171–186. doi: 10.1016/j.chmed.2022.03.004
   PubMed Web of Science ®Google Scholar
• Kaur K, Sharma R, Singh A, et al. Pharmacological and analytical aspects of alkannin/shikonin and their derivatives: An update from 2008 to 2022. Chin Herb Med. 2022;14:511–527. doi: 10.1016/j.chmed.2022.08.001
   PubMed Web of Science ®Google Scholar
• Huang B, Wu Y, Li C, et al. Molecular basis and mechanism of action of Albizia julibrissin in depression treatment and clinical application of its formulae. Chin Herb Med. 2023;15(2):201–213. doi: 10.1016/j.chmed.2022.10.004
   PubMed Web of Science ®Google Scholar
• Xie J, Xu D, Wang C, et al. Jiawei Xiaoyao San in treatment of anxiety disorder and anxiety: a review. Chin Herb Med. 2023;15(2):214–221. doi: 10.1016/j.chmed.2022.12.007
   PubMed Web of Science ®Google Scholar
• Friedrich RP, Pöttler M, Cicha I, et al. Nanomedicine for neuroprotection. Nanomedicine. 2019;14(2):127–130. doi: 10.2217/nnm-2018-0401
   PubMed Web of Science ®Google Scholar
• Musumeci T, Bonaccorso A, Puglisi G. Epilepsy disease and nose-to-brain delivery of polymeric nanoparticles: an overview. Pharmaceutics. 2019;11(3):118. doi: 10.3390/pharmaceutics11030118
   PubMed Web of Science ®Google Scholar
• Matias M, Santos AO, Silvestre S, et al. Fighting epilepsy with nanomedicines—Is this the right weapon? Pharmaceutics. 2023;15(2):306. doi: 10.3390/pharmaceutics15020306
   PubMed Web of Science ®Google Scholar
• Kou L, Bhutia YD, Yao Q, et al. Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types. Front Pharmacol. 2018;9:27. doi: 10.3389/fphar.2018.00027
   PubMed Web of Science ®Google Scholar
• Kou L, Yao Q, Zhang H, et al. Transporter-targeted nano-sized vehicles for enhanced and site-specific drug delivery. Cancers (Basel). 2020;12(10):2837. doi: 10.3390/cancers12102837
   PubMed Web of Science ®Google Scholar
• Lin L, Geng D, She D, et al. Targeted nanotheranostics for the treatment of epilepsy through in vivo hijacking of locally activated macrophages. Acta Biomater. 2024;174:314–330. doi: 10.1016/j.actbio.2023.11.027
   PubMed Web of Science ®Google Scholar
• Shi C, Zhang J, Wang H, et al. Trojan horse nanocapsule enabled in situ modulation of the phenotypic conversion of Th17 cells to Treg cells for the treatment of multiple sclerosis in mice. Adv Mater. 2023;35(11):e2210262. doi: 10.1002/adma.202210262
   PubMed Web of Science ®Google Scholar
• Rho JM, White HS. Brief history of anti-seizure drug development. Epilepsia Open. 2018;3(S2):114–119. doi: 10.1002/epi4.12268
   PubMedGoogle Scholar
• Hakami T. Efficacy and tolerability of antiseizure drugs. Ther Adv Neurol Disord. 2021;14:17562864211037430. doi: 10.1177/17562864211037430
   Web of Science ®Google Scholar
• Perucca E, Brodie MJ, Kwan P, et al. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19(6):544–556. doi: 10.1016/S1474-4422(20)30035-1
   PubMed Web of Science ®Google Scholar
• Ilyas-Feldmann M, Asselin MC, Wang S, et al. P-glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)-[11 C]verapamil PET. Epilepsia. 2020;61(7):1472–1480. doi: 10.1111/epi.16581
   PubMed Web of Science ®Google Scholar
• Achar A, Ghosh C. Multiple hurdle mechanism and blood-brain barrier in epilepsy: glucocorticoid receptor-heat shock proteins on drug regulation. Neural Regen Res. 2021;16(12):2427–2428. doi: 10.4103/1673-5374.313046
   PubMed Web of Science ®Google Scholar
• Kanner AM, Bicchi MM. Antiseizure medications for adults with epilepsy. A Review JAMA. 2022;327(13):1269–1281. doi: 10.1001/jama.2022.3880
   PubMed Web of Science ®Google Scholar
• Moores G, D’Souza R, Bui E. Antiseizure medications and pregnancy. CMAJ. 2021;193(32):E1253. doi: 10.1503/cmaj.210065
   PubMed Web of Science ®Google Scholar
• Ding J, Wang Y, Lin W, et al. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet. 2015;54:305–317. doi: 10.1007/s40262-014-0212-8
   PubMed Web of Science ®Google Scholar
• Wiebe S, Blume WT, Girvin JP, et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345(5):311–318. doi: 10.1056/NEJM200108023450501
   PubMed Web of Science ®Google Scholar
• Madaan P, Gupta A, Gulati S. Pediatric epilepsy surgery: indications and evaluation. Indian J Pediatr. 2021;88(10):1000–1006. doi: 10.1007/s12098-021-03668-x
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu H, Li H, et al. Severity grading, risk factors, and prediction model of complications after epilepsy surgery: a large-scale and retrospective study. Front Neurol. 2021;12:722478. doi: 10.3389/fneur.2021.722478
   PubMed Web of Science ®Google Scholar
• Baxendale S. The cognitive costs, contraindications and complications of epilepsy surgery in adults. Curr Opin Neurol. 2020;33(2):207–212. doi: 10.1097/WCO.0000000000000799
   PubMed Web of Science ®Google Scholar
• Khoo A, de Tisi J, Mannan S, et al. Reasons for not having epilepsy surgery. Epilepsia. 2021;62(12):2909–2919. doi: 10.1111/epi.17083
   PubMed Web of Science ®Google Scholar
• Rugg-Gunn F, Miserocchi A, McEvoy A. Epilepsy surgery. Pract Neurol. 2020;20:4–14. doi: 10.1136/practneurol-2019-002192
   PubMedGoogle Scholar
• Ryvlin P, Rheims S, Hirsch LJ, et al. Neuromodulation in epilepsy: state-of-the-art approved therapies. Lancet Neurol. 2021;20(12):1038–1047. doi: 10.1016/S1474-4422(21)00300-8
   PubMed Web of Science ®Google Scholar
• Zhang H, Jin B, You X, et al. Pharmacodynamic advantages and characteristics of traditional Chinese medicine in prevention and treatment of ischemic stroke. Chin Herb Med. 2023;15(4):496–508. doi: 10.1016/j.chmed.2023.09.003
   PubMed Web of Science ®Google Scholar
• A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The vagus nerve stimulation study group. Neurology. 1995;45(2):224–230. doi: 10.1212/WNL.45.2.224
   PubMed Web of Science ®Google Scholar
• Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia. 2010;51:899–908. doi: 10.1111/j.1528-1167.2010.02536.x
   PubMed Web of Science ®Google Scholar
• Morris GL 3rd, Gloss D, Buchhalter J, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2013;81:1453–1459. doi: 10.1212/WNL.0b013e3182a393d1
   PubMed Web of Science ®Google Scholar
• Rusek M, Pluta R, Ułamek-Kozioł M, et al. Ketogenic diet in Alzheimer’s disease. Int J Mol Sci. 2019;20(16):3892. doi: 10.3390/ijms20163892
   PubMed Web of Science ®Google Scholar
• Ułamek-Kozioł M, Czuczwar SJ, Januszewski S, et al. Ketogenic diet and epilepsy. Nutrients. 2019;11(10):2510. doi: 10.3390/nu11102510
   PubMed Web of Science ®Google Scholar
• Calderón N, Betancourt L, Hernández L, et al. A ketogenic diet modifies glutamate, gamma-aminobutyric acid and agmatine levels in the hippocampus of rats: a microdialysis study. Neurosci Lett. 2017;642:158–162. doi: 10.1016/j.neulet.2017.02.014
   PubMed Web of Science ®Google Scholar
• Barzegar M, Afghan M, Tarmahi V, et al. Ketogenic diet: overview, types, and possible anti-seizure mechanisms. Nutr Neurosci. 2021;24(4):307–316. doi: 10.1080/1028415X.2019.1627769
   PubMed Web of Science ®Google Scholar
• Heinrich M, Yao R, Xiao P. ‘Food and medicine continuum’ – why we should promote cross-cultural communication between the global east and West. Chin Herb Med. 2022;14(1):3–4. doi: 10.1016/j.chmed.2021.12.002
   PubMed Web of Science ®Google Scholar
• Hao D, Liu C. Deepening insights into food and medicine continuum within the context of pharmacophylogeny. Chin Herb Med. 2023;15(1):1–2. doi: 10.1016/j.chmed.2022.12.001
   PubMed Web of Science ®Google Scholar
• Ułamek-Kozioł M, Pluta R, Bogucka-Kocka A, et al. To treat or not to treat drug-refractory epilepsy by the ketogenic diet? That is the question. Ann Agric Environ Med. 2016;23(4):533–536. doi: 10.5604/12321966.1226841
   PubMed Web of Science ®Google Scholar
• Wells J, Swaminathan A, Paseka J, et al. Efficacy and safety of a ketogenic diet in children and adolescents with refractory epilepsy—a review. Nutrients. 2020;12(6):1809. doi: 10.3390/nu12061809
   PubMed Web of Science ®Google Scholar
• Yao Q, Chen R, Ganapathy V, et al. Therapeutic application and construction of bilirubin incorporated nanoparticles. J Control Release. 2020;328:407–424. doi: 10.1016/j.jconrel.2020.08.054
   PubMed Web of Science ®Google Scholar
• Kou L, Jiang X, Xiao S, et al. Therapeutic options and drug delivery strategies for the prevention of intrauterine adhesions. J Control Release. 2020;318:25–37. doi: 10.1016/j.jconrel.2019.12.007
   PubMed Web of Science ®Google Scholar
• Xu Y, Lv L, Wang Q, et al. Emerging application of nanomedicine-based therapy in acute respiratory distress syndrome. Colloids Surf B Biointerfaces. 2024;237:113869. doi: 10.1016/j.colsurfb.2024.113869
   PubMed Web of Science ®Google Scholar
• Chen R, Jiang Z, Cheng Y, et al. Multifunctional iron-apigenin nanocomplex conducting photothermal therapy and triggering augmented immune response for triple negative breast cancer. Int J Pharmaceut. 2024;655:124016. doi: 10.1016/j.ijpharm.2024.124016
   PubMed Web of Science ®Google Scholar
• Chen R, Zhai Y-Y, Sun L, et al. Alantolactone-loaded chitosan/hyaluronic acid nanoparticles suppress psoriasis by deactivating STAT3 pathway and restricting immune cell recruitment. Asian J Pharm Sci. 2022;17(2):268–283. doi: 10.1016/j.ajps.2022.02.003
   PubMed Web of Science ®Google Scholar
• Shen X, Sheng H, Zhang Y, et al. Nanomedicine-based disulfiram and metal ion co-delivery strategies for cancer treatment. Int J Pharm X. 2024;7:100248. doi: 10.1016/j.ijpx.2024.100248
   PubMedGoogle Scholar
• Kou L, Hou Y, Yao Q, et al. L-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2. Artif Cells Nanomed Biotechnol. 2018;46:1605–1616. doi: 10.1080/21691401.2017.1384385
   PubMed Web of Science ®Google Scholar
• Bao S, Zheng H, Ye J, et al. Dual targeting EGFR and STAT3 with erlotinib and alantolactone co-loaded PLGA nanoparticles for pancreatic cancer treatment. Front Pharmacol. 2021;12:625084. doi: 10.3389/fphar.2021.625084
   PubMed Web of Science ®Google Scholar
• Kou L, Huang H, Tang Y, et al. Opsonized nanoparticles target and regulate macrophage polarization for osteoarthritis therapy: A trapping strategy. J Control Release. 2022;347:237–255. doi: 10.1016/j.jconrel.2022.04.037
   PubMed Web of Science ®Google Scholar
• Kou L, Jiang X, Tang Y, et al. Resetting amino acid metabolism of cancer cells by ATB(0,+)-targeted nanoparticles for enhanced anticancer therapy. Bioact Mater. 2022;9:15–28. doi: 10.1016/j.bioactmat.2021.07.009
   PubMed Web of Science ®Google Scholar
• Chen R, Lin X, Wang Q, et al. Dual-targeting celecoxib nanoparticles protect intestinal epithelium and regulate macrophage polarization for ulcerative colitis treatment. Chem Eng J. 2023;452:139445. doi: 10.1016/j.cej.2022.139445
   Web of Science ®Google Scholar
• Kou L, Sun R, Jiang X, et al. Tumor microenvironment-responsive, multistaged liposome induces apoptosis and ferroptosis by amplifying oxidative stress for enhanced cancer therapy. ACS Appl Mater Interfaces. 2020;12(27):30031–30043. doi: 10.1021/acsami.0c03564
   PubMed Web of Science ®Google Scholar
• Jabir NR, Tabrez S, Firoz CK, et al. A synopsis of nano-technological approaches toward anti-epilepsy therapy: present and future research implications. Curr Drug Metab. 2015;16(5):336–345. doi: 10.2174/1389200215666141125142605
   PubMed Web of Science ®Google Scholar
• Jiang X, Jiang Z, Huang S, et al. Ultraviolet B radiation-induced JPH203-loaded keratinocyte extracellular vesicles exert etiological interventions for psoriasis therapy. J Control Release. 2023;362:468–478. doi: 10.1016/j.jconrel.2023.08.059
   PubMed Web of Science ®Google Scholar
• Kou L, Yao Q, Sun M, et al. Cotransporting Ion is a trigger for cellular endocytosis of transporter-targeting nanoparticles: a case study of high-efficiency SLC22A5 (OCTN2)-mediated carnitine-conjugated nanoparticles for oral delivery of therapeutic drugs. Adv Healthcare Mater. 2017;6(17):1700165. doi: 10.1002/adhm.201700165
   Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18. doi: 10.1016/j.colsurfb.2009.09.001
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen H, Huang L, et al. ATB(0,+)-targeted nanoparticles initiate autophagy suppression to overcome chemoresistance for enhanced colorectal cancer therapy. Int J Pharmaceut. 2023;641:123082. doi: 10.1016/j.ijpharm.2023.123082
   PubMed Web of Science ®Google Scholar
• Qi B, Ding Y, Zhang Y, et al. Biomaterial-assisted strategies to improve islet graft revascularization and transplant outcomes. Biomater Sci. 2024;12(4):821–836. doi: 10.1039/D3BM01295F
   PubMed Web of Science ®Google Scholar
• Deng S, Gigliobianco MR, Censi R, et al. Polymeric nanocapsules as nanotechnological alternative for drug delivery system: current status, challenges and opportunities. Nanomaterials (Basel). 2020;10(5):847. doi: 10.3390/nano10050847
   PubMedGoogle Scholar
• Adhikari C. Polymer nanoparticles-preparations, applications and future insights: a concise review. Polym Plast Technol Eng. 2021;1–29. doi: 10.1080/25740881.2021.1939715
   Web of Science ®Google Scholar
• Marin E, Briceño MI, Caballero-George C. Critical evaluation of biodegradable polymers used in nanodrugs. Int J Nanomedicine. 2013;8:3071–3090. doi: 10.2147/IJN.S47186
   PubMed Web of Science ®Google Scholar
• Zielińska A, Carreiró F, Oliveira AM, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16):3731. doi: 10.3390/molecules25163731
   PubMed Web of Science ®Google Scholar
• Bonilla L, Esteruelas G, Ettcheto M, et al. Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges. Epilepsia Open. 2022;7(Suppl 1):S121–s132. doi: 10.1002/epi4.12567
   PubMedGoogle Scholar
• Kaur IP, Bhandari R, Bhandari S, et al. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008;127(2):97–109. doi: 10.1016/j.jconrel.2007.12.018
   PubMed Web of Science ®Google Scholar
• Tabatt K, Kneuer C, Sameti M, et al. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J Control Release. 2004;97(2):321–332. doi: 10.1016/j.jconrel.2004.02.029
   PubMed Web of Science ®Google Scholar
• Mosallaei N, Jaafari MR, Hanafi-Bojd MY, et al. Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations. J Pharm Sci. 2013;102(6):1994–2004. doi: 10.1002/jps.23522
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery â–a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177. doi: 10.1016/S0939-6411(00)00087-4
   PubMed Web of Science ®Google Scholar
• Abudurexiti M, Xue J, Li X, et al. Curcumin/TGF-β1 siRNA loaded solid lipid nanoparticles alleviate cerebral injury after intracerebral hemorrhage by transnasal brain targeting. Colloids Surf B Biointerfaces. 2024;237:113857. doi: 10.1016/j.colsurfb.2024.113857
   PubMed Web of Science ®Google Scholar
• Neves AR, van der Putten L, Queiroz JF, et al. Transferrin-functionalized lipid nanoparticles for curcumin brain delivery. J Biotechnol. 2021;331:108–117. doi: 10.1016/j.jbiotec.2021.03.010
   PubMed Web of Science ®Google Scholar
• Xia X, Sun T, Zhao Y, et al. Bilirubin nanoparticles alleviate sepsis-induced acute lung injury by protecting pulmonary endothelia glycocalyx and reducing inflammation. ACS Appl Nano Mater. 2024. doi: 10.1021/acsanm.4c02015
   Web of Science ®Google Scholar
• Yao Q, Ye J, Chen Y, et al. Modulation of glucose metabolism through macrophage-membrane-coated metal-organic framework nanoparticles for triple-negative breast cancer therapy. Chem Eng J. 2024;480:148069. doi: 10.1016/j.cej.2023.148069
   Web of Science ®Google Scholar
• Huang H, Zheng S, Wu J, et al. Opsonization inveigles macrophages engulfing carrier-free bilirubin/JPH203 nanoparticles to suppress inflammation for osteoarthritis therapy. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2024:e2400713. doi: 10.1002/advs.202400713
   Google Scholar
• Yao Q, Tang Y, Dai S, et al. A biomimetic nanoparticle exerting protection against acute liver failure by suppressing CYP2E1 activity and scavenging excessive ROS. Adv Healthc Mater. 2023;12(24):e2300571. doi: 10.1002/adhm.202300571
   PubMed Web of Science ®Google Scholar
• Liu Y, Luo J, Chen X, et al. Cell membrane coating technology: a promising strategy for biomedical applications. Nanomicro Lett. 2019;11(1):100. doi: 10.1007/s40820-019-0330-9
   PubMed Web of Science ®Google Scholar
• Luk BT, Zhang L. Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release. 2015;220:600–607. doi: 10.1016/j.jconrel.2015.07.019
   PubMed Web of Science ®Google Scholar
• Zhu J, Yang Y, Ma W, et al. Antiepilepticus effects of tetrahedral framework nucleic acid via inhibition of gliosis-induced downregulation of glutamine synthetase and increased AMPAR internalization in the postsynaptic membrane. Nano Lett. 2022;22(6):2381–2390. doi: 10.1021/acs.nanolett.2c00025
   PubMed Web of Science ®Google Scholar
• Scioli-Montoto S, Sbaraglini ML, Cisneros JS, et al. Novel phenobarbital-loaded nanostructured lipid carriers for epilepsy treatment: From QbD to in vivo evaluation. Front Chem. 2022;10:908386. doi: 10.3389/fchem.2022.908386
   PubMed Web of Science ®Google Scholar
• Drion CM, van Scheppingen J, Arena A, et al. Effects of rapamycin and curcumin on inflammation and oxidative stress in vitro and in vivo — in search of potential anti-epileptogenic strategies for temporal lobe epilepsy. J Neuroinflammation. 2018;15(1):212. doi: 10.1186/s12974-018-1247-9
   PubMedGoogle Scholar
• Yavarpour-Bali H, Ghasemi-Kasman M, Pirzadeh M. Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders. Int J Nanomedicine. 2019;14:4449–4460. doi: 10.2147/IJN.S208332
   PubMed Web of Science ®Google Scholar
• Hashemian M, Anissian D, Ghasemi-Kasman M, et al. Curcumin-loaded chitosan-alginate-STPP nanoparticles ameliorate memory deficits and reduce glial activation in pentylenetetrazol-induced kindling model of epilepsy. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79:462–471. doi: 10.1016/j.pnpbp.2017.07.025
   PubMed Web of Science ®Google Scholar
• Matias M, Silvestre S, Falcão A, et al. Considerations and pitfalls in selecting the drug vehicles for evaluation of new drug candidates: Focus on in vivo pharmaco-toxicological assays based on the rotarod performance test. J Pharm Pharm Sci. 2018;21:110–118. doi: 10.18433/jpps29656
   PubMed Web of Science ®Google Scholar
• Ren T, Hu M, Cheng Y, et al. Piperine-loaded nanoparticles with enhanced dissolution and oral bioavailability for epilepsy control. Eur J Pharm Sci. 2019;137:104988. doi: 10.1016/j.ejps.2019.104988
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood–brain barrier. Neurobiol Dis. 2010;37(1):13–25. doi: 10.1016/j.nbd.2009.07.030
   PubMed Web of Science ®Google Scholar
• Xie J, Shen Z, Anraku Y, et al. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224:119491. doi: 10.1016/j.biomaterials.2019.119491
   PubMed Web of Science ®Google Scholar
• Han L, Jiang C. Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies. Acta Pharm Sin B. 2021;11(8):2306–2325. doi: 10.1016/j.apsb.2020.11.023
   PubMed Web of Science ®Google Scholar
• Löscher W. Epilepsy and alterations of the blood-brain barrier: cause or consequence of epileptic seizures or both? Handb Exp Pharmacol. 2022;273:331–350.
   PubMedGoogle Scholar
• Neves AR, Queiroz JF, Reis S. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnology. 2016;14(1):27. doi: 10.1186/s12951-016-0177-x
   PubMed Web of Science ®Google Scholar
• Siddiqui MA, Akhter J, Aarzoo D, et al. Resveratrol loaded nanoparticles attenuate cognitive impairment and inflammatory markers in PTZ-induced kindled mice. Int Immunopharmacol. 2021;101:108287. doi: 10.1016/j.intimp.2021.108287
   PubMed Web of Science ®Google Scholar
• Ugur Yilmaz C, Emik S, Orhan N, et al. Targeted delivery of lacosamide-conjugated gold nanoparticles into the brain in temporal lobe epilepsy in rats. Life Sci. 2020;257:118081. doi: 10.1016/j.lfs.2020.118081
   PubMed Web of Science ®Google Scholar
• Ammar HO, Ghorab MM, Mahmoud AA, et al. Lamotrigine loaded poly-ɛ-(d,l-lactide-co-caprolactone) nanoparticles as brain delivery system. Eur J Pharm Sci. 2018;115:77–87. doi: 10.1016/j.ejps.2018.01.028
   PubMed Web of Science ®Google Scholar
• Qushawy M, Prabahar K, Abd-Alhaseeb M, et al. Preparation and evaluation of carbamazepine solid lipid nanoparticle for alleviating seizure activity in pentylenetetrazole-kindled mice. Molecules. 2019;24(21):3971. doi: 10.3390/molecules24213971
   PubMed Web of Science ®Google Scholar
• Igartúa DE, Martinez CS, Temprana CF, et al. PAMAM dendrimers as a carbamazepine delivery system for neurodegenerative diseases: A biophysical and nanotoxicological characterization. Int J Pharm. 2018;544(1):191–202. doi: 10.1016/j.ijpharm.2018.04.032
   PubMedGoogle Scholar
• Cano A, Ettcheto M, Espina M, et al. Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy. Nanomedicine. 2018;14(4):1073–1085. doi: 10.1016/j.nano.2018.01.019
   PubMed Web of Science ®Google Scholar
• Yurtdaş Kırımlıoğlu G, Menceloğlu Y, Erol K, et al. In vitro/in vivo evaluation of gamma-aminobutyric acid-loadedN,N-dimethylacrylamide-based pegylated polymeric nanoparticles for brain delivery to treat epilepsy. J Microencapsul. 2016;33(7):625–635. doi: 10.1080/02652048.2016.1234515
   PubMed Web of Science ®Google Scholar
• Zhou Z, Li K, Chu Y, et al. ROS-removing nano-medicine for navigating inflammatory microenvironment to enhance anti-epileptic therapy. Acta Pharm Sin B. 2023;13(3):1246–1261. doi: 10.1016/j.apsb.2022.09.019
   PubMed Web of Science ®Google Scholar
• Zhou Z, Li K, Guo Y, et al. ROS/Electro dual-reactive nanogel for targeting epileptic foci to remodel aberrant circuits and inflammatory microenvironment. ACS Nano. 2023;17(8):7847–7864. doi: 10.1021/acsnano.3c01140
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yang L, Zheng Y, et al. Electro-responsive micelle-based universal drug delivery system for on-demand therapy in epilepsy. J Control Release. 2023;360:759–771. doi: 10.1016/j.jconrel.2023.07.024
   PubMed Web of Science ®Google Scholar
• Lopalco A, Ali H, Denora N, et al. Oxcarbazepine-loaded polymeric nanoparticles: development and permeability studies across in vitro models of the blood-brain barrier and human placental trophoblast. Int J Nanomedicine. 2015;10:1985–1996. doi: 10.2147/IJN.S77498
   PubMed Web of Science ®Google Scholar
• De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3:133–149. doi: 10.2147/IJN.S596
   PubMed Web of Science ®Google Scholar
• Fang Z, Chen S, Qin J, et al. Pluronic P85-coated poly(butylcyanoacrylate) nanoparticles overcome phenytoin resistance in P-glycoprotein overexpressing rats with lithium-pilocarpine-induced chronic temporal lobe epilepsy. Biomaterials. 2016;97:110–121. doi: 10.1016/j.biomaterials.2016.04.021
   PubMed Web of Science ®Google Scholar
• Zybina A, Anshakova A, Malinovskaya J, et al. Nanoparticle-based delivery of carbamazepine: a promising approach for the treatment of refractory epilepsy. Int J Pharm. 2018;547(1–2):10–23. doi: 10.1016/j.ijpharm.2018.05.023
   PubMedGoogle Scholar
• Wolfram J, Zhu M, Yang Y, et al. Safety of nanoparticles in medicine. Curr Drug Targets. 2015;16(14):1671–1681. doi: 10.2174/1389450115666140804124808
   PubMed Web of Science ®Google Scholar
• Zara GP, Cavalli R, Fundarò A, et al. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res. 1999;40(3):281–286. doi: 10.1006/phrs.1999.0509
   PubMed Web of Science ®Google Scholar
• Patel S, Chavhan S, Soni H, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target. 2011;19(6):468–474. doi: 10.3109/1061186X.2010.523787
   PubMed Web of Science ®Google Scholar
• Musumeci T, Serapide MF, Pellitteri R, et al. Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents. Eur J Pharm Biopharm. 2018;133:309–320. doi: 10.1016/j.ejpb.2018.11.002
   PubMed Web of Science ®Google Scholar
• Liu S, Yang S, Ho PC. Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain. Asian J Pharm Sci. 2018;13(1):72–81. doi: 10.1016/j.ajps.2017.09.001
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahmad R, Alrasheed RA, et al. Quantification and evaluations of catechin hydrate polymeric nanoparticles used in brain targeting for the treatment of epilepsy. Pharmaceutics. 2020;12(3):203. doi: 10.3390/pharmaceutics12030203
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahmad R, Qatifi SA, et al. A bioanalytical UHPLC based method used for the quantification of thymoquinone-loaded-PLGA-nanoparticles in the treatment of epilepsy. BMC Chem. 2020;14(1):10. doi: 10.1186/s13065-020-0664-x
   PubMed Web of Science ®Google Scholar